Data on PMV’s p53 reactivator prompt a 26% selloff before their presentation, and 48% afterwards.

Tempest Therapeutics confirms an earlier success with its lead project, and this time investors respond.

The once-hyped group’s most advanced hope is an allogeneic CD19 Car-T, where competition is fierce.

Ideaya and GSK join Novartis and Roche in the Werner helicase inhibitor race.

The acquisition brings closure for Mirati at last, though some investors will feel disappointed.

Bristol, AbbVie and Jiangsu HengRui move to enter clinical trials with undisclosed mechanisms of action.

But a US adcom slams Amgen’s oversight of Codebreak-200, as the group’s KRAS rival Mirati surges on takeover talk.